TH MEDICAL-B (02697) jumped more than 16%, and as of press time, it was up 13.63% at HK$74.6, with a turnover of HK$34.6794 million.
On the news front, TH MEDICAL-B recently announced that its organ perfusion system research had achieved a major breakthrough. It has successfully completed six preclinical experiments of extracorporeal cross-perfusion support therapy using genetically edited pig livers to assist non-human primate acute liver failure models, setting a record for stable liver function perfusion support therapy of up to 144 hours, with all six cases exceeding 72 hours. This is the world's first long-duration efficacy validation of the technology.
Industry experts said the results confirm the feasibility and safety of genetically edited pig liver extracorporeal perfusion support therapy for bridge treatment of liver failure, providing a new technical pathway for treating critically ill liver failure patients.
It is reported that the organ perfusion system underpinning this research is a modular organ medical device platform. It uses a universal core main unit paired with replaceable specialized tubing, organ chambers, perfusate and other consumables and configuration modules. Without replacing the main unit, it can carry out research applications related to normothermic perfusion preservation and extracorporeal life support for multiple organs including the liver, kidney, heart and lung, and has the technical potential to expand from isolated organ perfusion preservation to extracorporeal perfusion support therapy research.
Comments